195 research outputs found
Precise mapping of the CD95 pre-ligand assembly domain.
International audiencePre-association of CD95 at the plasma membrane is mandatory for efficient death receptor signaling. This homotrimerization occurs through self-association of an extracellular domain called the pre-ligand assembly domain (PLAD). Using novel molecular and cellular tools, we confirmed that CD95-PLAD is necessary to promote CD95 multimerization and plays a pivotal role in the transmission of apoptotic signals. However, while a human CD95 mutant deleted of the previously described PLAD domain (amino acids 1 to 66) fails to interact with its wild-type counterpart and trigger autonomous cell death, deletion of amino acids 1 to 42 does not prevent homo- or hetero (human/mouse)-oligomerization of CD95, and thus does not alter transmission of the apoptotic signal. Overall, these findings indicate that the region between amino acids 43 to 66 corresponds to the minimal motif involved in CD95 homotypic interaction and is necessary to convey an efficient apoptotic signal. Interfering with this PLAD may represent a new therapeutic strategy for altering CD95-induced apoptotic and non-apoptotic signals
Liver and brain differential expression of one-carbon metabolism genes during ontogenesis
One-carbon metabolism (1C metabolism) is of paramount importance for cell metabolism and mammalian development. It is involved in the synthesis or modification of a wide variety of compounds such as proteins, lipids, purines, nucleic acids and neurotransmitters. We describe here the evolution of expression of genes related to 1C metabolism during liver and brain ontogeny in mouse. The level of expression of 30 genes involved in 1C metabolism was quantified by RT-qPCR in liver and brain tissues of OF1 mice at E9, E11, E13, E15, E17, P0, P3, P5, P10, P15 developmental stages and in adults. In the liver, hierarchical clustering of the gene expression patterns revealed five distinct clades of genes with a first bifurcating hierarchy distinguishing two main developmental stages before and after E15. In the brain most of the 1C metabolism genes are expressed but at a lower levels. The gene expression of enzymes involved in 1C metabolism show dramatic changes during development that are tissue specific. mRNA expression patterns of all major genes involved in 1C metabolism in liver and brain provide clues about the methylation demand and methylation pathways during embryonic development
Translocator Protein-Mediated Stabilization of Mitochondrial Architecture during Inflammation Stress in Colonic Cells.
International audienceChronic inflammation of the gastrointestinal tract increasing the risk of cancer has been described to be linked to the high expression of the mitochondrial translocator protein (18 kDa; TSPO). Accordingly, TSPO drug ligands have been shown to regulate cytokine production and to improve tissue reconstruction. We used HT-29 human colon carcinoma cells to evaluate the role of TSPO and its drug ligands in tumor necrosis factor (TNF)-induced inflammation. TNF-induced interleukin (IL)-8 expression, coupled to reactive oxygen species (ROS) production, was followed by TSPO overexpression. TNF also destabilized mitochondrial ultrastructure, inducing cell death by apoptosis. Treatment with the TSPO drug ligand PK 11195 maintained the mitochondrial ultrastructure, reducing IL-8 and ROS production and cell death. TSPO silencing and overexpression studies demonstrated that the presence of TSPO is essential to control IL-8 and ROS production, so as to maintain mitochondrial ultrastructure and to prevent cell death. Taken together, our data indicate that inflammation results in the disruption of mitochondrial complexes containing TSPO, leading to cell death and epithelia disruption. This work implicates TSPO in the maintenance of mitochondrial membrane integrity and in the control of mitochondrial ROS production, ultimately favoring tissue regeneration
Rectal cancer with synchronous unresectable metastases: arguments for therapeutic choice
Environ 4 000 patients sont pris en charge chaque année en
France pour un cancer du rectum avec des métastases synchrones
jugées non résécables en réunion de concertation pluridisciplinaire
(RCP). Il n’existe pas de consensus sur la stratégie
thérapeutique à proposer et parmi les trois options possibles, les
critères de choix restent relativement imprécis.
– La chirurgie première est certes le meilleur traitement pour
contrôler les symptômes rectaux mais elle n’a pas démontré
qu’elle augmentait la survie et la résécabilité secondaire des
métastases par rapport aux autres options et comporte un
risque de résection incomplète, de complications pouvant
retarder ou empêcher la chimiothérapie, de progression accélérée
de la maladie métastatique et de mortalité comprise
entre 1 et 5 %.
– La radio-chimiothérapie première suivie d’une chirurgie permet
le contrôle des symptômes rectaux mais retarde la chimiothérapie
pour les métastases qui dominent le pronostic ; elle
expose aux mĂŞmes risques de complications que la chirurgie
première.
– La chimiothérapie première nous paraît intéressante en
absence de complications locales sévères (occlusion, hémorragie)
; elle est potentiellement efficace sur les mĂ©tastases Ă
distance qui conditionnent le pronostic et sur la tumeur primitive
qui répond souvent de manière similaire ; elle ne fige pas
la stratégie et offre la possibilité de l’adapter à chaque évaluation
selon la réponse, la tolérance et les possibilités de résection
(tumeur primitive et métastases).
Dans tous les cas, il est fondamental de discuter ces dossiers au
cas par cas en RCP pour adapter la stratégie thérapeutique aux
caractéristiques du patient, de la tumeur primitive et de l’extension
métastatique, ainsi qu’à la réponse obtenue aux traitements
proposés successivement.Rectal cancers with synchronous unresectable metastases are
diagnosed in about 4 000 patients. There is yet no consensus on
the therapeutic strategy for these cases which must be discussed
during multidisciplinary meeting. Three options are available
and arguments of choice remain relatively weak.
– First-line resection of the primary rectal tumour is indeed
the best treatment to control rectal symptoms but it does
not seem to improve survival and secondary resectability
of metastases when compared to other options; moreover
incomplete resection or complications may delay chemotherapy, accelerate the metastastic process and mortality
rate ranges from 1 to 5%.
– First-line radio-chemotherapy followed by surgery allows for
controlling rectal symptoms but delays chemotherapy for
metastases dominating the prognosis; it exposes the patients
to the same morbidity and mortality as first-line surgery.
– First-line chemotherapy is the third valid option in the absence
of major rectal symptoms (occlusion, haemorrhage); chemotherapy
is potentially efficient on distant metastases bearing a
high prognosis impact and on the primary rectal tumour, which
often has a similar response. First-line chemotherapy allows
for adapting the therapeutic strategy after each evaluation
according to the tumour response, side effects and possibility
of resection (primary rectal tumour and metastases).
In all cases, medical records of such patients should be discussed
during a multidisciplinary meeting to adapt the therapeutic
strategy to the patient’s characteristics, primary rectal tumor,
metastases staging and evolution
Long-term neurological outcome of a cohort of 80 patients with classical organic acidurias.
International audienceBACKGROUND: Classical organic acidurias including methylmalonic aciduria (MMA), propionic aciduria (PA) and isovaleric aciduria (IVA) are severe inborn errors of the catabolism of branched-chain amino acids and odd-numbered chain fatty acids, presenting with severe complications. METHODS: This study investigated the long-term outcome of 80 patients with classical organic aciduria (38 with MMA, 24 with PA and 18 with IVA) by integrating clinical, radiological, biochemical and genetic data. RESULTS: Patients were followed-up for a mean of 14 years [age 3.3-46.3 years]. PA included a greater number of patients with abnormal neurological examination (37% in PA, 24% in MMA and 0% in IVA), lower psychometric scores (abnormal evaluation at age 3 years in 61% of patients with PA versus 26% in MMA and 18% in IVA) and more frequent basal ganglia lesions (56% of patients versus 36% in MMA and 17% in IVA). All patients with IVA presented a normal neurological examination and only 1/3 presented cognitive troubles. Prognosis for MMA was intermediate. Biochemical metabolite analysis excluding acute decompensations revealed significant progressive increases of glycine, alanine and glutamine particularly in PA and possibly in MMA but no correlation with neurological outcome. A significant increase of plasma methylmalonic acid was found in MMA patients with intellectual deficiency (mean level of 199 mumol/L versus 70 mumol/L, p < 0.05), with an estimated significant probability of severe outcome for average levels between birth and age 6 years above 167 mumol/L. Urinary 3-hydroxypropionate (3-HP) levels were significantly higher in PA patients with intellectual deficiency (mean level of 68.9 mumol/mmol of creatinine versus 34.6 mumol/mmol of creatinine, p < 0.01), with an estimated significant probability of severe outcome for average levels between birth and age 6 years above 55 mumol/mmol. As for molecular analysis, prognosis of MMA patients with mutations involving the MMAA gene was better compared to patients with mutations involving the MUT gene. CONCLUSION: Propionic aciduria had the most severe neurological prognosis. Our radiological and biochemical data are consistent with a mitochondrial toxicity mechanism. Follow-up plasma MMA and urinary 3-HP levels may have prognostic significance calling for greater efforts to optimize long-term management in these patients
- …